(Q33966376)

30 July 2017

1 reference

title

Review article: maintenance treatment of Crohn's disease (English)

1 reference

30 July 2017

0 references

Biancone L

1

1 reference

30 July 2017

Tosti C

2

1 reference

30 July 2017

Fina D

3

1 reference

30 July 2017

Fantini M

4

1 reference

30 July 2017

De Nigris F

5

1 reference

30 July 2017

Geremia A

6

1 reference

30 July 2017

Pallone F

7

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Alimentary Pharmacology & Therapeutics

30 July 2017

1 reference

30 July 2017

17 Suppl 2

1 reference

30 July 2017

31-37

1 reference

Preliminary evidence for genetic anticipation in Crohn's disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.20.X

10.1046/J.1365-2036.17.S2.20.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference